Alglucerase

Jump to: navigation, search
Alglucerase
Systematic (IUPAC) name
Human beta-glucocerebrosidase
Identifiers
CAS number 37228-64-1
ATC code A16AB01
PubChem  ?
DrugBank DB00088
Chemical data
Formula C2532H3854N672O711S16 
Mol. mass 55597.4 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 3.6–10.4 min
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

WikiDoc Resources for Alglucerase

Articles

Most recent articles on Alglucerase

Most cited articles on Alglucerase

Review articles on Alglucerase

Articles on Alglucerase in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Alglucerase

Images of Alglucerase

Photos of Alglucerase

Podcasts & MP3s on Alglucerase

Videos on Alglucerase

Evidence Based Medicine

Cochrane Collaboration on Alglucerase

Bandolier on Alglucerase

TRIP on Alglucerase

Clinical Trials

Ongoing Trials on Alglucerase at Clinical Trials.gov

Trial results on Alglucerase

Clinical Trials on Alglucerase at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alglucerase

NICE Guidance on Alglucerase

NHS PRODIGY Guidance

FDA on Alglucerase

CDC on Alglucerase

Books

Books on Alglucerase

News

Alglucerase in the news

Be alerted to news on Alglucerase

News trends on Alglucerase

Commentary

Blogs on Alglucerase

Definitions

Definitions of Alglucerase

Patient Resources / Community

Patient resources on Alglucerase

Discussion groups on Alglucerase

Patient Handouts on Alglucerase

Directions to Hospitals Treating Alglucerase

Risk calculators and risk factors for Alglucerase

Healthcare Provider Resources

Symptoms of Alglucerase

Causes & Risk Factors for Alglucerase

Diagnostic studies for Alglucerase

Treatment of Alglucerase

Continuing Medical Education (CME)

CME Programs on Alglucerase

International

Alglucerase en Espanol

Alglucerase en Francais

Business

Alglucerase in the Marketplace

Patents on Alglucerase

Experimental / Informatics

List of terms related to Alglucerase

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues.[1]

Ceredase is the trade name of a citrate buffered solution of alglucerase that was manufactured by Genzyme Corporation from human placental tissue.[1] It is given intravenously in the treatment of Type 1 Gaucher's disease. This was the first drug appoved as an enzyme replacement therapy.[1]

It was approved by the FDA in 1991.[2] It has been withdrawn from the market[3][4] due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture[1] (see imiglucerase).

References

  1. 1.0 1.1 1.2 1.3 Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012;6:81-106. doi: 10.2147/DDDT.S14395. Epub 2012 Apr 18. PMID 22563238 (free full text)
  2. World Health Organization. Regulatory Matters WHO Drug Information 5:3) 1991. p 123
  3. Aetna. Last reviewed 8 August, 2014 Clinical Policy Bulletin Number: 0442: Enzyme-replacement Therapy for Lysosomal Storage Disorders
  4. FDA Prescription and Over-the-Counter Drug Product List. 32ND Edition Cumulative Supplement Number 3: March 2012. Additions/Deletions for Prescription Drug Product List

External links


Linked-in.jpg